Lynn Wang, MD
Professor, Division of Genomic and Molecular Pathology
Founding Medical Director
Genomic and Molecular Pathology
University of Chicago Medical Center
Chicago, IL, USA
Exactly what does it mean that a tumor sample has a mutation or rearrangement? Exactly what is being measured? Is the presence of a mutation on an NGS panel an “all-or–none” phenomenon or are there additional quantitative levels of characterization ...
What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE?
What categories of genomic alterations are identified by the method of genomic profiling you are familiar with? Do they include all classes of alterations, i.e. base substitutions, insertions/deletions, copy number alterations and rearrangements? ...
What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with ...
What is FoundationOne Heme? How accurate are its detection rates and how is it being used to detect genomic alterations that can impact diagnosis, therapy selection and prognosis in hematologic cancers?